OBJECTIVES: This trial examined the efficacy of a stress management program in reducing neuroimaging markers of multiple sclerosis (MS) disease activity. METHODS: A total of 121 patients with relapsing forms of MS were randomized to receive stress management therapy for MS (SMT-MS) or a wait-list control condition. SMT-MS provided 16 individual treatment sessions over 24 weeks, followed by a 24-week post-treatment follow-up. The primary outcome was the cumulative number of new gadolinium-enhancing (Gd+) brain lesions on MRI at weeks 8, 16, and 24. Secondary outcomes included new or enlarging T2 MRI lesions, brain volume change, clinical exacerbation, and stress. RESULTS:SMT-MS resulted in a reduction in cumulative Gd+ lesions (p = 0.04) and greater numbers of participants remained free of Gd+ lesions during the treatment (76.8% vs 54.7%, p = 0.02), compared to participants receiving the control treatment. SMT-MS also resulted in significantly reduced numbers of cumulative new T2 lesions (p = 0.005) and a greater number of participants remaining free of new T2 lesions (69.5% vs 42.7%, p = 0.006). These effects were no longer detectable during the 24-week post-treatment follow-up period. CONCLUSIONS: This trial indicates that SMT-MS may be useful in reducing the development of new MRI brain lesions while patients are in treatment. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that SMT-MS, a manualized stress management therapy program, reduced the number of Gd+ lesions in patients with MS during a 24-week treatment period. This benefit was not sustained beyond 24 weeks, and there were no clinical benefits. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT00147446.
RCT Entities:
OBJECTIVES: This trial examined the efficacy of a stress management program in reducing neuroimaging markers of multiple sclerosis (MS) disease activity. METHODS: A total of 121 patients with relapsing forms of MS were randomized to receive stress management therapy for MS (SMT-MS) or a wait-list control condition. SMT-MS provided 16 individual treatment sessions over 24 weeks, followed by a 24-week post-treatment follow-up. The primary outcome was the cumulative number of new gadolinium-enhancing (Gd+) brain lesions on MRI at weeks 8, 16, and 24. Secondary outcomes included new or enlarging T2 MRI lesions, brain volume change, clinical exacerbation, and stress. RESULTS: SMT-MS resulted in a reduction in cumulative Gd+ lesions (p = 0.04) and greater numbers of participants remained free of Gd+ lesions during the treatment (76.8% vs 54.7%, p = 0.02), compared to participants receiving the control treatment. SMT-MS also resulted in significantly reduced numbers of cumulative new T2 lesions (p = 0.005) and a greater number of participants remaining free of new T2 lesions (69.5% vs 42.7%, p = 0.006). These effects were no longer detectable during the 24-week post-treatment follow-up period. CONCLUSIONS: This trial indicates that SMT-MS may be useful in reducing the development of new MRI brain lesions while patients are in treatment. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that SMT-MS, a manualized stress management therapy program, reduced the number of Gd+ lesions in patients with MS during a 24-week treatment period. This benefit was not sustained beyond 24 weeks, and there were no clinical benefits. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT00147446.
Authors: Maria Pia Sormani; Laura Bonzano; Luca Roccatagliata; Gary R Cutter; Gian Luigi Mancardi; Paolo Bruzzi Journal: Ann Neurol Date: 2009-03 Impact factor: 10.422
Authors: David C Mohr; Stacey L Hart; Laura Julian; Claudine Catledge; Lara Honos-Webb; Lea Vella; Edwin T Tasch Journal: Arch Gen Psychiatry Date: 2005-09
Authors: Stefan M Gold; David C Mohr; Inge Huitinga; Peter Flachenecker; Esther M Sternberg; Christoph Heesen Journal: Trends Immunol Date: 2005-10-07 Impact factor: 16.687
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: David C Mohr; Lucy Epstein; Tracy L Luks; Donald Goodkin; Darcy Cox; Alison Goldberg; Cynthia Chin; Sarah Nelson Journal: J Consult Clin Psychol Date: 2003-12
Authors: Stefan M Gold; Mary-Frances O'Connor; Raja Gill; Kyle C Kern; Yonggang Shi; Roland G Henry; Daniel Pelletier; David C Mohr; Nancy L Sicotte Journal: Hum Brain Mapp Date: 2012-07-30 Impact factor: 5.038
Authors: Martin Weygandt; Lil Meyer-Arndt; Janina Ruth Behrens; Katharina Wakonig; Judith Bellmann-Strobl; Kerstin Ritter; Michael Scheel; Alexander U Brandt; Christian Labadie; Stefan Hetzer; Stefan M Gold; Friedemann Paul; John-Dylan Haynes Journal: Proc Natl Acad Sci U S A Date: 2016-11-07 Impact factor: 11.205